SCHEMBL30135903

SCHEMBL30135903

O=C1CCC(c2ccc(N3CCC(NCC4CCC(NC(=O)OCc5ccccc5)CC4)CC3)c(F)c2)C(=O)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
DPP4 P27487 6/20 0.39
DPP7 Q9UHL4 6/20 0.39
KCNH2 Q12809 4/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSK P43235 1/20 0.38
NPY2R P49146 1/20 0.38
GPR55 Q9Y2T6 2/20 0.37
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25253102 0.88 NPY2R (0.39) KDM1ANPY2RDDB1CRBN
SCHEMBL30135834 0.87 ALDH1A1 (0.38) ALDH1A1GAAKDM1AMAOBDPP4
SCHEMBL30135798 0.86 ALDH1A1 (0.38) ALDH1A1GAAKDM1AMAOBDPP4
SCHEMBL30135729 0.84 CRBN (0.44) GAADDB1CRBN
SCHEMBL25822081 0.84 DDB1 (0.45) KDM1ANPY2RDRD2DDB1CRBN
SCHEMBL30981145 0.83 ENPP2 (0.39) ALDH1A1GAAKDM1AMAOBDPP4
SCHEMBL30965622 0.83 ENPP2 (0.37) ALDH1A1GAAKDM1AMAOBDPP4
SCHEMBL30135928 0.80 CRBN (0.37) ALDH1A1KDM1AMAOBDPP4DPP7
SCHEMBL25335434 0.80 CRBN (0.37) KDM1ANPY2RDDB1CRBN
SCHEMBL25035469 0.79 CRBN (0.39) NPY2RDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
EP-4157849-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2023-04-05 EP disclosed
WO-2023018238-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885GAA 2658/4885KDM1A 1866/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 ALDH1A1 2752/4885GAA 2669/4885KDM1A 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.